Amniotic membrane allograft for diabetic foot ulcers

The clinical problem

An estimated 19–34% of people with diabetes will develop a foot ulcer in their lifetime, and DFUs precede the majority of non-traumatic lower-extremity amputations ^[1]. Standard of care for a DFU includes glycemic control, offloading, infection management, debridement, and moist wound healing. Advanced wound-care products — including cellular and tissue-based products (CTPs) — are considered adjunctively when an ulcer fails to progress on standard care after approximately 4 weeks ^[2].

What amniotic membrane allografts are

Amniotic membrane is the innermost layer of the placenta. After donor screening, recovery, and processing under FDA 21 CFR Part 1271 (HCT/P) requirements, amniotic membrane is preserved as a dehydrated or cryopreserved allograft for clinical use ^[3]. The membrane is rich in extracellular matrix proteins (collagen types I, III, IV, V, and VI), growth factors, and anti-inflammatory cytokines that have been studied for their role in wound healing.

Amniotic allografts are regulated by the FDA under section 361 of the Public Health Service Act when they meet the criteria of minimal manipulation and homologous use. Products that exceed those criteria are regulated as 351 biologics and require pre-market approval ^[3].

Evidence in DFU care

Multiple randomized controlled trials have evaluated amniotic membrane allografts versus standard of care for chronic, non-healing DFUs. Published systematic reviews report higher rates of complete wound closure at 12 weeks with amniotic membrane allograft plus standard care than with standard care alone ^[4]. Effect sizes vary by product, study population (ulcer size, duration, Wagner grade), and protocol (weekly vs biweekly application).

Clinicians should interpret the literature with two cautions:

1. Many trials are industry-sponsored. Methodological quality and outcome definitions vary across studies.
2. "Amniotic membrane allograft" is not a single product. Dehydrated and cryopreserved products differ in handling, shelf life, and reported composition. Evidence for one product does not automatically generalize to another.

When amniotic allograft is typically considered

In most wound-care protocols, an amniotic allograft is considered after:

• Diagnosis and treatment of underlying infection
• Vascular assessment (ABI, toe pressures, or transcutaneous oximetry as indicated)
• Adequate offloading (total contact cast or equivalent for plantar ulcers)
• Sharp debridement to a clean wound bed
• 4 weeks of standard care without ≥50% area reduction ^[2]

Application is typically weekly or biweekly per the product''s instructions for use and the local LCD frequency limit. Wound measurement at each visit (L × W, depth, undermining) supports both clinical decision-making and reimbursement documentation.

Patient selection considerations

Patient factors that may influence outcomes include glycemic control (HbA1c), nutritional status, smoking status, lower-extremity perfusion, and adherence to offloading. Amniotic allografts are not a substitute for revascularization, infection control, or offloading; they are an adjunct.

Documentation

Documentation for each application should include:

• Wound measurement and photograph (if part of protocol)
• Product manufacturer, lot, Q-code, total graft size, applied area, discarded area
• Date of debridement and findings
• Confirmation of offloading and infection management
• Plan for re-evaluation

Related resources

• Dehydrated vs cryopreserved amniotic grafts
• Graft size selection and wound measurement
• Amniotic allograft Q-codes: a clinician reference